Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2018
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms APFAO
- 02 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 02 May 2018 Planned number of patients changed from 37 to 43.
- 01 Jan 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.